<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249908</url>
  </required_header>
  <id_info>
    <org_study_id>ID-BVCL-103</org_study_id>
    <nct_id>NCT04249908</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function</brief_title>
  <official_title>A Non-randomized, Open, Single-dose, Parallel Designed Clinical Study to Evaluate Safety and Pharmacokinetic Characteristics After Oral Administration of Besivo® in Patients With Renal Impairment and Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral&#xD;
      dose of Besifovir and its metabolite, LB80331, in participants with normal and impaired renal&#xD;
      function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 13, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) profiles of LB80331: Area under the plasma concentration-time curve (AUC)_0-t</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>This endpoint will measure the plasma PK profiles of LB80331. PK parameters that will be measured include AUC_0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) profiles of LB80331: Cmax</measure>
    <time_frame>Predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72 hours</time_frame>
    <description>This endpoint will measure the plasma PK profiles of LB80331. PK parameters that will be measured include Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of Besifovir as measured by incidence of adverse events and laboratory abnormalities</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>Review of adverse events and safety labs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Renal Impairment (RI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate RI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe RI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifovir Dipivoxil Maleate</intervention_name>
    <description>Besifovir 150 mg q.d.</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Mild Renal Impairment (RI)</arm_group_label>
    <arm_group_label>Moderate RI</arm_group_label>
    <arm_group_label>Severe RI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Individuals:&#xD;
&#xD;
          1. Have no clinically relevant abnormalities identified by a detailed medical history,&#xD;
             full physical examination, including vital signs, 12-lead electrocardiogram (ECG), or&#xD;
             clinical laboratory tests.&#xD;
&#xD;
          2. Patients who were explained about the purpose, methods and effects of the clinical&#xD;
             trial and then, signed a written consent form&#xD;
&#xD;
        Individuals with mild, moderate, or severe renal impairment must also meet the following&#xD;
        additional inclusion criteria to be eligible for participation in this study:&#xD;
&#xD;
          1. Age of 19 to 65 years at the time of the screening visit.&#xD;
&#xD;
          2. A person whose body mass index (BMI) is greater than 18 kg/m^2 and less than 27 kg/m^2&#xD;
             at the time of the screening visit.&#xD;
&#xD;
          3. Individuals with severe renal impairment, estimated Glomerular Filtration Rate (eGFR)&#xD;
             must be 15-29 mL/min/1.73m^2 (using the Modification of Diet in Renal Disease (MDRD)&#xD;
             method) at the time of the screening visit.&#xD;
&#xD;
             Individuals with moderate renal impairment, eGFR must be 30-59 mL/min/1.73m^2 (using&#xD;
             the MDRD method) at the time of the screening visit.&#xD;
&#xD;
             Individuals with mild renal impairment, eGFR must be 60-89 mL/min/1.73m^2 (using the&#xD;
             MDRD method) at the time of the screening visit.&#xD;
&#xD;
          4. Stable renal impairment with no clinically significant changes within 3 months prior&#xD;
             to the screening visit.&#xD;
&#xD;
        Individuals with normal renal function must also meet the following additional inclusion&#xD;
        criteria to be eligible for participation in this study:&#xD;
&#xD;
          1. A healthy adult who is at least 19 years old at the time of the screening visit.&#xD;
&#xD;
          2. A person whose BMI is greater than 18 kg/m^2 and less than 30 kg/m^2 at the time of&#xD;
             the screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history&#xD;
&#xD;
               -  Clinically significant cardiovascular, respiratory, renal, gastrointestinal,&#xD;
                  hepatic, hematologic, neurologic, thyroid or any other medical illness or&#xD;
                  psychiatric disorder, as determined by the Investigator&#xD;
&#xD;
               -  A person with a history of chronic hepatitis B&#xD;
&#xD;
               -  A person with a history of gastrointestinal disorders (ex. Crohn's disease,&#xD;
                  ulcerative colitis, etc.) or surgery (except for simple appendectomy or&#xD;
                  herniotomy) that may affect the absorption of the investigational product.&#xD;
&#xD;
          2. A person who shows the following in the diagnostic test during the screening period.&#xD;
&#xD;
               -  Positive screening test for Hepatitis B Virus surface Antigen (HBs-Ag), human&#xD;
                  immunodeficiency virus (HIV) test, hepatitis C test, Venereal Disease Research&#xD;
                  Laboratory (VDRL) test&#xD;
&#xD;
               -  Clinically significant abnormal ECG findings.&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and aminotransferase (ALT) values exceed the&#xD;
                  upper limit of normal range (ULN) by more than 2 times.&#xD;
&#xD;
               -  Total Bilirubin, Gamma-Glutamyl Transpeptidase (γ-GTP) &gt; 1.5 X ULN, Creatine&#xD;
                  Phosphokinase (CK) &gt; 2 X ULN&#xD;
&#xD;
               -  Clinically significant laboratory abnormalities or abnormalities which are deemed&#xD;
                  to interfere with the ability to interpret study data.&#xD;
&#xD;
          3. A person who has a history of drug abuse or whose urine drug screening test result&#xD;
             during the screening period came back positive for abusive drug use.&#xD;
&#xD;
          4. The contraindication of comedication drugs and diets&#xD;
&#xD;
               -  A person who has been administered with the investigational product or a&#xD;
                  bioequivalence study drug in another clinical trial within 180 days of the&#xD;
                  screening visit.&#xD;
&#xD;
          5. Other criteria&#xD;
&#xD;
               -  A woman whose urine human chorionic gonadotropin (hCG) test results were positive&#xD;
                  and who is pregnant or breastfeeding.&#xD;
&#xD;
               -  A person who has donated partial or full amount of blood within 60 days of the&#xD;
                  screening visit, who has given blood through apheresis within 28 days, or who has&#xD;
                  been transfused within 28 days.&#xD;
&#xD;
               -  History of regular alcohol intake &gt; 21 units per week of alcohol before 28 dyas&#xD;
                  or unwilling to abstain from alcohol for study period before the start of&#xD;
                  admission until the final Completion Visit assessments.&#xD;
&#xD;
               -  A person who has smoked excessively within 28 days of the screening visit or&#xD;
                  whose (&gt; 10 cigarettes/day) or◦ who can't quit smoking during the trial&#xD;
&#xD;
               -  Consumption of caffeine products within 28 days (caffeine drink &gt; 7 glass/day)&#xD;
                  who can't abstain from caffeine products during the trial&#xD;
&#xD;
               -  Consumption of any grapefruit juice within 48 hours before administration of&#xD;
                  investigational product or subjects who can't abstain from grapefruit juice&#xD;
                  during the trial&#xD;
&#xD;
               -  Fertile subjects who are unwilling or unable to use a highly effective method of&#xD;
                  contraception as outlined in this protocol for the duration of the study and for&#xD;
                  at least 2 weeks after the administration of investigational product.&#xD;
&#xD;
               -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
               -  Subjects who are considered to be unacceptable in this study under the opinion of&#xD;
                  the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kim Min Jung</last_name>
    <phone>8225263179</phone>
    <email>mjkim90@ildong.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

